ATE433994T1 - Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung - Google Patents

Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung

Info

Publication number
ATE433994T1
ATE433994T1 AT04801809T AT04801809T ATE433994T1 AT E433994 T1 ATE433994 T1 AT E433994T1 AT 04801809 T AT04801809 T AT 04801809T AT 04801809 T AT04801809 T AT 04801809T AT E433994 T1 ATE433994 T1 AT E433994T1
Authority
AT
Austria
Prior art keywords
production
long
insulin derivatives
lasting effects
insulin molecule
Prior art date
Application number
AT04801809T
Other languages
English (en)
Inventor
Dominique Bridon
Jean-Paul Castaigne
Xicai Huang
Roger Leger
Martin Robitaille
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE433994(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE433994T1 publication Critical patent/ATE433994T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT04801809T 2003-07-25 2004-07-26 Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung ATE433994T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49011003P 2003-07-25 2003-07-25
US55658504P 2004-03-25 2004-03-25
PCT/CA2004/001409 WO2005012346A1 (en) 2003-07-25 2004-07-26 Long lasting insulin derivatives and methods thereof

Publications (1)

Publication Number Publication Date
ATE433994T1 true ATE433994T1 (de) 2009-07-15

Family

ID=34118817

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04801809T ATE433994T1 (de) 2003-07-25 2004-07-26 Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung

Country Status (15)

Country Link
US (1) US20060241019A1 (de)
EP (2) EP1648933B1 (de)
JP (2) JP2007520441A (de)
AT (1) ATE433994T1 (de)
AU (2) AU2004261319B2 (de)
BR (1) BRPI0412252A (de)
CA (1) CA2526957C (de)
DE (1) DE602004021603D1 (de)
DK (1) DK1648933T3 (de)
EA (1) EA008433B1 (de)
ES (1) ES2328579T3 (de)
NO (1) NO20060888L (de)
PL (1) PL1648933T3 (de)
SI (1) SI1648933T1 (de)
WO (1) WO2005012346A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
AU2007247109B2 (en) * 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
EP2114437A2 (de) 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modifizierte peptide mit corticotropinfreisetzungsfaktor und verwendungen davon
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2262539B1 (de) 2008-04-01 2015-07-15 Novo Nordisk A/S Insulin-albumin-konzentrate
WO2010088286A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
EP2836508B1 (de) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulinformulierungen
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
CA2926701A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20160001391A (ko) * 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CN107531762A (zh) * 2015-05-07 2018-01-02 科德克希思公司 青霉素g酰化酶
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
CN113855678A (zh) * 2021-09-08 2021-12-31 武汉生命奥义生物科技有限公司 一种用于辅助治疗二型糖尿病的组合物
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509120A (en) * 1966-12-28 1970-04-28 Squibb & Sons Inc N-terminal mono- and diaminoacyl-insulin
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
HUP0004169A3 (en) * 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1052994A2 (de) * 1998-02-02 2000-11-22 Trustees Of Tufts College Verwendung von dipetidylpeptidasehemmer zur regulierung des glukosemetabolismus
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
CA2334859A1 (en) * 1998-06-12 1999-12-23 Kings College London Insulin analogue
JP2002534059A (ja) * 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
AU765753B2 (en) * 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1299418A1 (de) * 2000-07-10 2003-04-09 BTG INTERNATIONAL LIMITED (Company No. 2664412) Insulinderivat und seine synthese
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
AU2002254940A1 (en) * 2001-03-12 2002-09-24 Novartis Pharma Gmbh Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2003218635A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
US9040664B2 (en) * 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations

Also Published As

Publication number Publication date
CA2526957A1 (en) 2005-02-10
EP2085406A1 (de) 2009-08-05
JP2012062311A (ja) 2012-03-29
AU2004261319B2 (en) 2010-12-23
CA2526957C (en) 2011-07-12
DK1648933T3 (da) 2009-09-07
EP1648933A1 (de) 2006-04-26
EA008433B1 (ru) 2007-06-29
HK1091843A1 (en) 2007-01-26
NO20060888L (no) 2006-04-25
BRPI0412252A (pt) 2006-09-19
AU2004261319A1 (en) 2005-02-10
WO2005012346A1 (en) 2005-02-10
EP1648933B1 (de) 2009-06-17
ES2328579T3 (es) 2009-11-16
DE602004021603D1 (de) 2009-07-30
JP2007520441A (ja) 2007-07-26
PL1648933T3 (pl) 2010-01-29
AU2011201278A1 (en) 2011-04-07
EA200600305A1 (ru) 2006-06-30
SI1648933T1 (sl) 2010-01-29
US20060241019A1 (en) 2006-10-26
EP1648933A4 (de) 2007-02-28

Similar Documents

Publication Publication Date Title
DE602004021603D1 (de) Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
WO2005012347A3 (en) Novel insulin derivatives
DE50111495D1 (de) Künstliche sauerstoffträger aus vernetztem modifizierten human- oder schweinehämoglobin, verfahren zu ihrer herstellung aus gereinigtem material, sowie deren verwendung
ATE540980T1 (de) Proteinkomplex mit immunglobulinfragment und verfahren zu dessen herstellung
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
EP2292636A3 (de) Prozess, um Antikörper und therapeutische Produkte zu konzentrieren
ATE469161T1 (de) Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
WO2007141565A3 (en) Amino-acid functional siloxanes, methods of preparation and applications
JP2020513019A5 (de)
CA2385857A1 (en) C peptide for improved preparation of insulin and insulin analogs
EP2275439A3 (de) Neuartige Insulinderivate
NO20084002L (no) Peptider og peptid derivater savel som farmasoytiske sammensetninger inneholdende det samme
WO2019012545A1 (en) SELF-ASSEMBLY HYBRID HYDROGELS FORMED OF A SHORT AROMATIC PEPTIDE AND AN AROMATIC AMINO ACID
WO2006050930A3 (en) Conjugates with enhanced cell uptake activity
ATE464566T1 (de) Verfahren zur markierung phosphorylierten peptiden, komplexverbindunger, verfahren zu deren herstellung und zwischenprodukte
EP2046813A2 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
ATE419012T1 (de) Verwendung von 2,5-dihydroxybenzolsulfonsäure- derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion
WO2006014429A3 (en) Cidofovir peptide conjugates as prodrugs
DE50312246D1 (de) Verfahren zur herstellung eines mit titandioxid pigmentierten polyamids
DK1506295T3 (da) Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf
AU5576298A (en) Novel amide derivatives and medicinal compositions thereof
CN1907234A (zh) 带生物膜的血管瘤夹
ATE556054T1 (de) Verfahren zur herstellung von loperamid
ZA200608865B (en) Biologically active peptide VAPEEHPTLLTEAPLNPK derivatives
DE60309605D1 (de) SUBSTITUIERTE i1,4öBENZODIOXINi2,3-EöISOINDOL-DERIVATEN, IHR VERFAHREN ZUR HERSTELLUNG UND IHRE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648933

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1648933

Country of ref document: EP